Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Ultra-short-acting neuromuscular blockers with advantages over available agents

Nov. 17, 1998

Ono-1603 compared to tacrine for protection against age-induced neuronal apoptosis

Nov. 16, 1998

RJR-2403: CNS-selective nicotinic agonist with long-lasting beneficial effects on cognition

Nov. 16, 1998

Selective 5-HT7 receptor antagonist affects circadian rhythms in animal models

Nov. 16, 1998

Preclinical studies indicate OP-1 is effective three days after stroke

Nov. 16, 1998

SB team attempts to identify the source of antiparkinsonian activity of SKF-83959

Nov. 13, 1998

Neurobiological Technologies initiates phase IIb trial of memantine

Nov. 13, 1998

SCRAS presents new series of NOS and lipid peroxidation inhibitors

Nov. 13, 1998

Ligand and Elan finalize strategic alliance

Nov. 13, 1998

SB-205553 used to investigate role of 5-HT2C receptor antagonists in PD therapy

Nov. 13, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...